According to analysts at Market Business Insights, the Global Cholera Vaccine Market size is worth USD 0.42 Billion in 2025 and is projected to reach USD 1.06 Billion by 2035, growing at a CAGR (Compound Annual Growth Rate) of 9.7% from 2026 to 2035. Key trends include expanding national immunization programs, increasing international procurement, recurring outbreak preparedness initiatives, growing humanitarian vaccination campaigns, manufacturing capacity expansion, cold-chain optimization, digital inventory management, advanced vaccine manufacturing technologies, and stronger collaboration among governments, global health organizations, and vaccine suppliers.
Cholera Vaccine Market Overview
The global Cholera Vaccine Market is witnessing significant growth as governments, international health organizations, and humanitarian agencies strengthen infectious disease prevention and outbreak preparedness programs. Cholera vaccination has become an important component of public health strategies in regions affected by recurring outbreaks, vulnerable sanitation infrastructure, population displacement, and inadequate access to safe water and healthcare services.
Unlike conventional pharmaceutical markets that rely heavily on retail and individual consumption, cholera vaccine demand is largely driven by institutional procurement. Government immunization programs, international procurement agencies, public health organizations, hospitals, humanitarian groups, and other institutional buyers play a major role in determining purchasing volumes. Long-term procurement agreements are increasingly supporting predictable demand while enabling manufacturers to optimize production schedules and maintain adequate supply for routine vaccination campaigns and emergency responses.
The market is also benefiting from investments in manufacturing resilience, automated production systems, quality analytics, fill-finish capabilities, and cold-chain infrastructure. Vaccine manufacturers are expanding production capacity and improving operational efficiency to address increasing procurement requirements while maintaining compliance with stringent international quality and regulatory standards.
Asia Pacific currently dominates the market, accounting for approximately 44% of global revenue in 2025, supported by extensive immunization initiatives, recurring disease surveillance programs, public health investments, and sustained institutional procurement across endemic areas. North America and Europe remain important markets due to Travel Medicine, emergency preparedness, vaccine research, humanitarian programs, and advanced healthcare infrastructure. Latin America and the Middle East & Africa are also expected to provide substantial opportunities as governments strengthen vaccination preparedness, disease surveillance, and healthcare coordination.
Overall, the Cholera Vaccine Market is expected to experience robust long-term growth as vaccination programs increasingly transition from short-term outbreak response toward structured preventive healthcare strategies supported by diversified manufacturing networks, international procurement agreements, and stronger public health preparedness.
Recent Industry Development
- February 2025 ā EuBiologics expanded vaccine production capacity to strengthen global institutional supply commitments, supporting greater manufacturing scalability and supply reliability for public health vaccination programs.
Key Takeaways from the Report
- Global cholera prevention initiatives and expanding national immunization strategies are accelerating demand for vaccines across endemic and high-risk regions.
- Oral Cholera Vaccines accounted for approximately 82% of global market revenue in 2025, supported by their suitability for mass vaccination campaigns and emergency deployment.
- Government Immunization Programs represent the leading distribution channel due to their central role in national vaccination strategies and population-level disease prevention.
- Government Immunization Programs are projected to record the fastest expansion, with an estimated CAGR exceeding 10% during the forecast period.
- Public-sector vaccination initiatives generated more than 70% of procurement demand, highlighting the strong influence of institutional purchasing decisions.
- Asia Pacific accounted for approximately 44% of global revenue in 2025 and remains the leading regional market due to recurring vaccination campaigns and extensive public health investments.
- Advanced vaccine manufacturing technologies are supporting production scalability, quality consistency, supply reliability, and operational efficiency.
- Humanitarian organizations are creating additional procurement opportunities through emergency vaccination programs responding to population displacement, natural disasters, conflicts, and disease outbreaks.
- Digital inventory management, demand forecasting, logistics monitoring, and automated manufacturing systems are emerging as important technologies across the vaccine supply chain.
- Manufacturing expansion and diversified international procurement agreements are strengthening the long-term resilience and competitive positioning of vaccine suppliers.
Top Players
- Valneva SE
- Bharat Biotech International Limited
- EuBiologics Co., Ltd.
- Sanofi
- Pfizer Inc.
- GlaxoSmithKline plc
- Merck & Co., Inc.
- Serum Institute of India Pvt. Ltd.
- Biological E. Limited
- Emergent BioSolutions Inc.
- CSL Limited
- Bavarian Nordic A/S
Report Coverage
Our market research reports provide comprehensive insights that are essential for strategic decision-making. We cover all key aspects of the market, including dynamics such as drivers, restraints, opportunities, and challenges, alongside the latest industry trends. Our analysis includes an in-depth technology roadmap, product life cycle evaluation, and PESTLE analysis, ensuring a thorough understanding of the market environment. We also assess GDP growth outlooks, examine regional market landscapes, and evaluate the impact of major events such as the COVID-19 pandemic. Additionally, our reports feature a detailed competitive landscape, including company market shares and profiles, providing actionable intelligence to empower your business strategies.
Latest Announcement
- September 2025 ā Serum Institute of India expanded fill-finish capabilities to improve supply flexibility for public immunization programs, supporting greater manufacturing resilience and the ability to address institutional vaccination requirements.